Abstract

Nicotine despite being the addictive component in cigarettes, is not the most toxic. The increased morbidity and mortality due to cigarette smoking can be blamed on various additives which are carcinogenic and toxic in nature. To achieve zero rates of cigarette smoking is a theoretical and idealistic target, but practically, the most feasible option is to adhere to harm minimization. This concept recognizes that not all Nicotine containing products are equally harmful and the ones which are safer can be promoted to increase their utilization, eventually reducing the rates of cigarette smoking as well as its associated health hazards. The Nicotine delivering product, along with being safe should also be satisfying and acceptable to cigarette smokers, so as to encourage them to switch to the better option. A tangible impact on public health will be created only if this change is followed by a major part of the population. An essential point to remember is that harm minimization does not substitute for tobacco prevention and cessation, rather it is a complementary plan for smokers who are unwilling or unable to quit. Nicotine replacement therapy, (remodeled or novel) Nicotine and tobacco products, psychological interventions and alternative therapies can be implemented individually or in combination for smoking cessation, depending on patient preference and comfort. This paper contains a detailed view on application, precautions and efficacy of various Nicotine delivery products. Key Messages: Nicotine although addictive, is not directly responsible for all the health hazards of tobacco consumption. Cigarette smoke has more than 7000 compounds that are harmful and lethal. Various compounds present in tobacco smoke such as carcinogens, toxicants, particulate matter and carbon monoxide are also responsible for the increased health risks related to tobacco smoking.

• 1.   Le Foll et al. Tobacco and nicotine use. Nat Rev Dis Primers. 2022;8(19).
• 2.   Nikki Bozinoff et al. Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efÀcacy of treatment. Expert Review of Respiratory Medicine. 2018;12:9:793-804.
• 3.   Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); OfÀce on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US);2010.
• 4.   Tiwari RK et al. Nicotine Addiction: Neurobiology and Mechanism. J Pharmacopuncture. 2020;23(1):1-7.
• 5.   Singh SK et al. Tobacco use and cessation among a nationally representative sample of men in India, 2019-2021. J Smok Cessat; 2023:4292647.
• 6.   Wang R et al. Prevalence of non-communicable diseases and its association with tobacco smoking cessation intention among current smokers in Shanghai, China. Tob Induc Dis; 2022.(20):106.
• 7.   Jha P et al. A nationally representative casecontrol study of smoking and death in India. N Engl J Med. 2008; 358(11):1137-1147.
• 8.   Khan, Yusra et al. Cigarette Smoking and Neurological Disorders: From Exposure to Therapeutic Interventions. 2021.
• 9.   Niaura R. Re-thinking nicotine and its effects. The Steven A. Schroeder National Institute for Tobacco Research and Policy Studies; 2019.
• 10.   Mendiola-Precoma J, Berumen LC, Padilla K and Garcia-Alcocer G: Therapies for prevention and treatment of Alzheimer's disease. Biomed Res Int.2016;2589276.
• 11.   Grossberg GT: Cholinesterase inhibitors for the treatment of Alzheimer's disease: Getting on and staying on. Curr Ther Res Clin Exp. 2003;64:216-235.
• 12.   Cheng Q and Yakel JL: The effect of α7 nicotinic receptor activation on glutamatergic transmission in the hippocampus. Biochem Pharmacol. 2015;97:439-444.
• 13.   Barber M, Stewart D, Grosset D and MacPhee G: Patient and carer perception of the management of Parkinson's disease after surgery. Age Ageing. 2001;30:171-172.
• 14.   Kinoshita KI, Tada Y, Muroi Y, Unno T and Ishii T: Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning. Life Sci. 2015;137:28-36.
• 15.   Ma C, Liu Y, Neumann S and Gao X: Nicotine from cigarette smoking and diet and Parkinson disease: A review. Transl Neurodegener. 2017;6:18.
• 16.   Pi HJ, Otmakhov N, El Gaamouch F, Lemelin D, De Koninck P and Lisman J: CaMKII control of spine size and synaptic strength: Role of phosphorylation states and nonenzymatic action. Proc Natl Acad Sci USA. 2010;107:14437-14442.
• 17.   Aleisa AM, Alzoubi KH, Gerges NZ and Alkadhi KA: Chronic psychosocial stressinduced impairment of hippocampal LTP: Possible role of BDNF. Neurobiol Dis 22: 453-462, 2006. 79.
• 18.   Kannichamy V, Antony I, Mishra V, et al. (October 22, 2020) Transdermal Nicotine as a Treatment Option for Ulcerative Colitis: A Review. Cureus.12(10):e11096.
• 19.   Stratton K et al. Clearing the smoke: the science base for tobacco harm reduction--executive summary. Tob Control. 2001;10(2):189-195.
• 20.   Hatsukami DK et al. Tobacco harm reduction: Past history, current controversies and a proposed approach for the future. Prev Med. 2020;140:106099.
• 21.   Abrams DB et al. Harm Minimization and Tobacco Control: Reframing Societal Views of Nicotine Use to Rapidly Save Lives. Annu Rev Public Health. 2018;39:193-213.
• 22.   Clive Bates. “Regulation, when less is more”. Presentation to E-cigarette Summit, 2013.
• 23.   Kozlowski Lt et al. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tobacco Control. 2001;10:201-203.
• 24.   Moore D et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and metaanalysis. BMJ. 2009;338:b1024
• 25.   Molyneux A. Nicotine replacement therapy. BMJ. 2004;328(7437):454-456.
• 26.   Flowers, Lee. Nicotine Replacement Therapy. American Journal of Psychiatry Residents' Journal. 2016;11(6).
• 27.   Wadgave U et al. Nicotine Replacement Therapy: An Overview. Int J Health Sci (Qassim). 2016;10(3):425-435.
• 28.   Guide to Prescribing Nicotine Replacement Therapy (NRT). Published by Ministry of Health, New Zealand Government. August 2021.
• 29.   Patel, Apexa et al. Methods of Smoking Cessation: A Review. Journal of national accreditation board for hospitals and health care providers. 2016;3.1-8.
• 30.   Christine Vinci. Cognitive Behavioral and Mindfulness-Based Interventions for Smoking Cessation: a Review of the Recent Literature. Curr Oncol Rep. 2021;22(6):58.
• 31.   Anne McCarthy et al. Harms and beneÀts of e-cigarettes and heat-not-burn tobacco products: A literature map. 2020. Published by Health Research Board, Dublin.
• 32.   Patrice Marques et al. An updated overview of e-cigarette impact on human health. Respir Res. 2021;22:151.
• 33.   Tattan-Birch H et al. Heated tobacco products for smoking cessation and reducing smoking prevalence. Cochrane Database Syst Rev. 2022;1(1):CD013790.
• 34.   Slob W et al. A Method for Comparing the Impact on Carcinogenicity of Tobacco Products: A Case Study on Heated Tobacco versus Cigarettes. Risk Anal. 2020;40(7):1355-1366.
• 35.   Heydari GH et al. A Comparative Study on Tobacco Cessation Methods: A Quantitative Systematic Review. Int J Prev Med. 2014;5:673-8.
• 36.   Lund M et al. Methods Used in Smoking Cessation and Reduction Attempts: Findings from Help-Seeking Smokers. J Smok Cessat. 2021:6670628.
• 37.   Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews 2016, Issue 9.
• 38.   https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-iqos-tobacco-heating-system-reduced-exposure-information.

Data Sharing Statement

Funding